map kinase p38 a

p38 MAP Kinase Inhibitor Ⅵ是一种有效的p38 MAP Kinase 抑制剂，具有抗炎活性。

p38 MAP Kinase-IN-1 (Compound 4) 是一种p38抑制剂，可用于研究炎症和自身免疫反应的过程。

p38 MAPK Inhibitor 是p38 MAPK 激酶的有效抑制剂（IC50＝ 35 nM）。p38 MAPK Inhibitor 抑制癌基因RAS 诱导的衰老。

EO-1606 是一种 p38 MAP 激酶抑制剂 ，具有抗炎活性，可用于研究阿尔茨海默症和皮炎 。

PD 169316 是一种细胞渗透性 p38 MAP 激酶抑制剂，IC50值为 89 nM。它可选择性地抑制磷酸化 p38 的激酶活性。

Panaxydol has anti-cancer activity, can inhibit the growth and apoptosis of cancer cells, the signaling mechanisms involve a [Ca(2+)](i) increase, JNK and p38 MAPK activation, cAMP, MAP kinase and ROS generation through NADPH oxidase and mitochondria.

SB 242235 是一种有效的选择性 p38 MAP 激酶抑制剂，可能是细胞因子介导疾病的有效疗法，在人的软骨细胞中 IC50值为 1.0 μM。

AZD 1152 is an orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50= 0.36 nM).1AZD 1152 is converted to AZD 1152-HQPA in plasma. Inhibition of Aurora B results in disruption of spindle checkpoint functions and chromosome alignment, resulting in inhibition of cytokinesis followed by apoptosis.2,3AZD 1152 inhibits tumor xenograft growthin vivo.4,5 1.Mortlock, A.A., Foote, K.M., Heron, N.M., et al.Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinaseJ. Med. Chem.50(9)2213-2224(2007) 2.Popescu, R., Heiss, E.H., Ferk, F., et al.Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cellsMutation Research709-71060-66(2011) 3.Moore, A.S., Blagg, J., Linardopoulos, S., et al.Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemiasLeukemia24(4)671-678(2010) 4.Wilkinson, R.W., Odedra, R., Heaton, S.P., et al.AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosisClin. Cancer. Res13(12)3682-3688(2007) 5.Yang, J., Ikezoe, T., Nishioka, C., et al.AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivoBlood110(6)2034-2040(2007)

RPR-200765A is a potent and selective inhibitor of p38 MAP kinase (IC50 = 50 nM). It inhibits LPS-stimulated TNFalpha release both in vitro, from human monocytes (EC50 = 110 nM), and in vivo in Balb c mice (ED50 = 6 mg kg). At oral doses between 10 and 30 mg kg day it reduces the incidence and progression in the rat streptococcal cell wall (SCW) arthritis model when administered in either prophylactic or therapeutic dosing regimens. The compound, which is a mesylate salt and exists as a stable monohydrate, shows good oral bioavailabiltiy (F = 50% in the rat) and excellent chemical stability. The data from the SCW disease model suggests that RPR200765A could exhibit a profile of disease modifying activity in rheumatoid arthritis (RA) patients which is not observed with current drug therapies.

SC-68376 is a potent, reversible, cell-permeable, ATP-competitive, and selective inhibitor of p38 MAP kinase.

p38 Kinase inhibitor 4 (compound 135) 是高效的 p38 MAP Kinase 抑制剂，具有显著的生物活性。

(S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively).